GSK’s cancer drug Jemperli has secured priority review by the U.S. Food and Drug Administration (FDA). A significant trial revealed that a notable number of patients showed no signs of rectal tumors for at least one year after treatment. This decision by the FDA could change the treatment approach for certain rectal cancers. If Jemperli is approved, patients may skip chemotherapy, radiation, and surgery, transforming first-line care options.
Regulatory Expedite
The FDA set a decision deadline for February 2027. However, the application qualifies for accelerated consideration under the National Priority Voucher program, indicating a possibility for an earlier ruling. Jemperli’s submission is also under Project Orbis, allowing synchronized international review channels.
AZUR‑1 Trial Results
The AZUR‑1 trial forms the basis of this review. It is a global Phase II study testing Jemperli as the sole treatment for untreated stage II/III dMMR/MSI‑H locally advanced rectal cancer. The trial met its primary objective by showing clinical complete responses (cCR12) lasting at least 12 months. GSK senior vice president Hesham Abdullah mentioned that AZUR‑1 presents a significant improvement over traditional treatments.
A total of 154 patients participated, each receiving nine cycles of Jemperli over six months. Interim safety results were consistent with the known safety profile of the drug.
Shifting Away From Chemoradiation
Traditional treatment for this cancer subtype has relied on a sequence of chemotherapy, radiation, and surgery. Although typically effective, these procedures have enduring impacts. Abdullah noted that traditional treatments aim to cure but often affect patients’ quality of life and can lead to death from cancer spread.
Jemperli may become the first approved immunotherapy that helps some patients avoid chemotherapy, radiation, and surgery entirely.
Quality‑of‑Life Considerations
The potential to forego surgery is a vital part of the AZUR‑1 results. Despite the effectiveness of existing treatments, they frequently impose a long-term toll on patients’ lives.
Post-treatment issues include the permanent use of a colostomy bag and conflicts with sexual, bowel, and urinary functions; psychological effects and fertility impacts are also common. If Jemperli becomes a first-line treatment, selected patients could avoid or delay these adverse outcomes.
Understanding Tumor Response
AZUR‑1 builds upon earlier work demonstrating PD‑1 blockade’s efficacy without chemoradiation. Tumors with dMMR/MSI‑H have numerous genetic alterations, allowing greater visibility to the immune system. Jemperli enhances the immune system’s attack by removing inhibitory signals.
Identifying dMMR/MSI‑H through biomarker testing is crucial, but it does not ensure every patient will respond. However, these findings could reshape clinical approaches to treating this cancer.
Future Directions and Regulatory Timeline
The FDA plans to finalize its decision by February 2027. However, involvement in the National Priority Voucher program may lead to an earlier conclusion. GSK is also seeking coordinated approval through Project Orbis, emphasizing the urgency of their application.
Abdullah mentioned that this accelerated process might lead to earlier FDA action. If approved, Jemperli would be the first immunotherapy capable of delaying invasive treatments. Medical professionals would likely need to adapt diagnostic processes to include earlier biomarker testing.
GSK’s Growing Oncology Initiatives
GSK’s oncology sector has been expanding, with Jemperli playing a core role in its cancer strategies. The company’s shares have increased by 9.7% this year, reflecting confidence in their research and developments.
Abdullah emphasized that the AZUR‑1 milestone marks a crucial phase in delivering scientific advances to patients. GSK continues advancing Phase 3 trials in gastrointestinal cancers where immunotherapy could meet existing treatment gaps. Detailed interim results will be shared later this year.